Ronald Muhlenkamp

Ronald Muhlenkamp

Last Update: 08-13-2018

Number of Stocks: 37
Number of New Stocks: 1

Total Value: $262 Mil
Q/Q Turnover: 2%

Countries: USA
Details: Top Buys | Top Sales | Top Holdings  Embed:

Ronald Muhlenkamp' s Profile & Performance

Profile

Ronald H. Muhlenkamp is the founder and president of Muhlenkamp & Company, Inc., and portfolio manager for the company's self-named mutual fund (MUHLX). Muhlenkamp is a patient value investor. The stocks in his portfolio stay an average of 10 years.

Web Page:http://www.muhlenkamp.com/

Investing Philosophy

He is a value guru who believes that over time, stock prices do reflect the values of the underlying businesses. When picking stocks, he looks for companies with solid balance sheets, and a return on equity capital (ROE) of 15% or better. Although his methods change with inflation and interest rates, he currently looks for companies with a P/E ratio lower than the companies’ ROE and expected growth rates. He focuses on the long-term "Business of Investing" because he thinks that it is more profitable and more reliable. As a long-term investor, his "normal" position is to be 100% invested in corporate stocks.

Historical Allocation of Stock, Bonds, Cash

Total Holding History

Performance of Muhlenkamp  Fund

YearReturn (%)S&P500 (%)Excess Gain (%)
201718.7721.71-2.9
2016-3.711.99-15.7
2015-6.211.24-7.5
3-Year Cumulative7.3 (2.4%/year)38 (11.3%/year)-30.7 (-8.9%/year)
20140.6413.47-12.8
201334.4332.32.1
5-Year Cumulative45.1 (7.7%/year)107.2 (15.7%/year)-62.1 (-8%/year)
201212.5215.99-3.5
2011-4.741.9-6.6
20106.1415.05-8.9
200931.4926.355.1
2008-40.39-36.79-3.6
10-Year Cumulative29.4 (2.6%/year)125 (8.4%/year)-95.6 (-5.8%/year)
2007-9.665.14-14.8
20064.0815.85-11.8
20057.884.833.1
200424.5110.713.8
200348.0728.1919.9
15-Year Cumulative142 (6.1%/year)307.7 (9.8%/year)-165.7 (-3.7%/year)
2002-19.92-21.581.7
20019.33-11.7621.1
200025.3-9.7535.0
199911.420.4-9.0
19983.2228.7-25.5
20-Year Cumulative205.3 (5.7%/year)294.5 (7.1%/year)-89.2 (-1.4%/year)
199733.2833.47-0.2
199629.9622.497.5
199532.938.04-5.1
1994-7.20.4-7.6
199318.110.088.0
25-Year Cumulative670.2 (8.5%/year)883.9 (9.6%/year)-213.7 (-1.1%/year)
199215.87.628.2
199145.430.4714.9
1990-14.8-3.1-11.7
198912.531.69-19.2

Top Ranked Articles

Celgene Acquires Company Investigating Cancer Warfare Drug Juno Therapeutics stock jumped 27% after $9 billion deal was announced
One of the largest biopharmaceutical players in the world, Celgene Corp. (NASDAQ:CELG), has announced a $9 billion deal to acquire Juno Therapeutics Inc. (NASDAQ:JUNO) as part of its plans to ramp up development of experimental blood-cancer drugs. Read more...
Ronald Muhlenkamp Boosts Express Scripts, AutoZone, Bristol-Myers Positions Guru’s largest buys of the 1st quarter
Ronald Muhlenkamp (TradesPortfolio), the founder and president of Muhlenkamp & Co. Inc., bought shares of the following stocks in the first quarter. Read more...
Ronald Muhlenkamp Dumps One Pharmaceutical Company in Favor of Another Guru releases 2nd-quarter portfolio
Ronald Muhlenkamp (Trades, Portfolio), leader of investment firm Muhlenkamp & Co. Inc., disclosed in his second-quarter portfolio that he exchanged his Bristol-Myers Squibb Co. (NYSE:BMY) holding for a position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ). Read more...
Is Muhlenkamp on a Roll Again? After a decade of dismal returns, the guru's performance has been strong over the past year
Ronald Muhlenkamp's Largest Sales of the 4th Quarter Guru trims ON Semiconductor, exits Dynagas, Energy Transfer Partners
Ronald Muhlenkamp (TradesPortfolio), founder of Muhlenkamp & Company, sold shares of the following stocks during the fourth quarter. Read more...
» More Ronald Muhlenkamp Articles

Commentaries and Stories

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Ronald Muhlenkamp Dumps One Pharmaceutical Company in Favor of Another Guru releases 2nd-quarter portfolio Ronald Muhlenkamp - Ronald Muhlenkamp Dumps One Pharmaceutical Company In Favor Of Another
Ronald Muhlenkamp (Trades, Portfolio), leader of investment firm Muhlenkamp & Co. Inc., disclosed in his second-quarter portfolio that he exchanged his Bristol-Myers Squibb Co. (NYSE:BMY) holding for a position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ). More...

MUHLENKAMP, BUYS, SELLS, 2Q


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Ronald Muhlenkamp Boosts Express Scripts, AutoZone, Bristol-Myers Positions Guru’s largest buys of the 1st quarter Ronald Muhlenkamp - Ronald Muhlenkamp Boosts Express Scripts, AutoZone, Bristol-Myers Positions
Ronald Muhlenkamp (TradesPortfolio), the founder and president of Muhlenkamp & Co. Inc., bought shares of the following stocks in the first quarter. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Ronald Muhlenkamp’s Top 5 Sales of the 1st Quarter Guru divested 17 positions from his portfolio Ronald Muhlenkamp - Ronald Muhlenkamp’s Top 5 Sales Of The 1st Quarter
Ronald Muhlenkamp (Trades, Portfolio), leader of Muhlenkamp & Co. Inc., disclosed he divested 17 positions from his portfolio in the first quarter. More...

RONALD, MUHLENKAMP, SELLS, 1Q, 2018


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Ronald Muhlenkamp's Largest Sales of the 4th Quarter Guru trims ON Semiconductor, exits Dynagas, Energy Transfer Partners Ronald Muhlenkamp - Ronald Muhlenkamp's Largest Sales Of The 4th Quarter
Ronald Muhlenkamp (TradesPortfolio), founder of Muhlenkamp & Company, sold shares of the following stocks during the fourth quarter. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Ron Muhlenkamp's 4th Quarter 2017 Shareholder Letter Review of markets and holdings Ronald Muhlenkamp - Ron Muhlenkamp's 4th Quarter 2017 Shareholder Letter
If you had told us a year ago that the market would rise 20% in 2017, we would have been skeptical. Yet, here we are at the end of the year and the S&P 500 Total Return Index was up 21.83% for 2017. The S&P 500 Index was up 19.42%. (The difference is the Total Return Index includes dividends.) Technology stocks led the charge; health care, consumer discretionary, and industrials also beat the average. Every other sector delivered below-average returns with energy and telecommunication services posting losses for the year. Our performance was quite close to the S&P 500 Index all year. (Please refer to the 12/31/2017 Fact Sheet for our final performance numbers.) Apple, Inc. (NASDAQ:AAPL), ON Semiconductor Corporation (ON), and Universal Display Corp. (NASDAQ:OLED) contributed the most to our performance this year, while Teva Pharmaceutical Industries (NYSE:TEVA), Spirit Airlines (NYSE:SAVE), and Allergan PLC (NYSE:AGN) were the biggest drags. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Celgene Acquires Company Investigating Cancer Warfare Drug Juno Therapeutics stock jumped 27% after $9 billion deal was announced Ken Fisher,Ronald Muhlenkamp - Celgene Acquires Company Investigating Cancer Warfare Drug
One of the largest biopharmaceutical players in the world, Celgene Corp. (NASDAQ:CELG), has announced a $9 billion deal to acquire Juno Therapeutics Inc. (NASDAQ:JUNO) as part of its plans to ramp up development of experimental blood-cancer drugs. More...

PHARMACEUTICALS, CANCER, T-CELLS, IMMUNOTHERAPY, BLOOD CANCERS, AUTOIMMUNE DISEASE


  • Currently 5.00/5

Rating: 5.0/5 (1 vote)

Ronald Muhlenkamp 3rd Quarter Shareholder Letter Muhlenkamp discusses markets and investing Ronald Muhlenkamp - Ronald Muhlenkamp 3rd Quarter Shareholder Letter
From a market perspective, this has been a quiet summer. As of 9/30/2017, the S&P 500* was up 6.63% over the last six months with hardly a dip. Low economic growth continues on a global basis, none of the major central banks have altered course in any fashion, inflation remains low, second quarter earnings came in nicely, etc. We won’t bore you (this time!) by enumerating the things we’re watching that haven’t changed since we wrote about them in June. There have been a couple of surprises: three destructive hurricanes and escalating tensions with North Korea (which the markets have mostly ignored). We believe that while the hurricanes have had a massive impact on the affected areas, their impact on the national economy will be fairly small and temporary. We believe war with North Korea is unlikely. We’ll keep an eye on developments and update our assessment as events unfold. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Is Muhlenkamp on a Roll Again? After a decade of dismal returns, the guru's performance has been strong over the past year Ronald Muhlenkamp, Warren Buffett - Is Muhlenkamp On A Roll Again?
More...

GURUS, RON MUHLENKAMP, TOM MUHLENKAMP, BENJAMIN GRAHAM, MUHLENKAMP MEMORANDUM, INTELLIGENT INVESTMENT MANAGEMENT, MUHLENKAMP & COMPANY, MUHLENKAMP FUND, FUNDAMENTAL SECURITY ANALYSIS, CYCLICALITY,


  • Currently 4.00/5

Rating: 4.0/5 (2 votes)

Spirit Airlines Is a Buy Again Priced just below where it was a year ago, the airline continues to demonstrate growth Robert Olstein, Ronald Muhlenkamp - Spirit Airlines Is A Buy Again
Out of the major airlines, Spirit Airlines Inc. (NYSE:SAVE) has the best return potential for investors. It is trading near a 52-week low because of cancelled flights in relation to a feud with pilots in May. Its union wanted a compensation package of $1.9 billion, which would have drastically raised Spirit’s costs over the next five years, while the company's counter was for $440 million over the same period. Both parties rejected the respective offers and remain in open contract negotiations. More...

AIRLINES, DELTA, SPIRIT, UNITED AIRLINES, AMERICAN AIRLINES


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Ronald Muhlenkamp Adds 7 New Stocks to Portfolio Guru’s largest investment was in media and entertainment company Ronald Muhlenkamp,Dodge & Cox,Daniel Loeb,Barrow H - Ronald Muhlenkamp Adds 7 New Stocks To Portfolio
Muhlenkamp & Co. Inc. founder Ronald Muhlenkamp (Trades, Portfolio) purchased seven new holdings in the first quarter. They are Twenty-First Century Fox Inc. (NASDAQ:FOXA), Dow Chemical Co. (DOW), Microchip Technology Inc. (NASDAQ:MCHP), Cabot Oil & Gas Corp. (NYSE:COG), Eldorado Gold Corp. (NYSE:EGO), Ameriprise Financial Inc. (NYSE:AMP) and The Cooper Companies Inc. (NYSE:COO). More...

MUHLENKAMP, BUYS, 1Q, 2017


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Ronald Muhlenkamp Gains 4 New Holdings, Sells 2 Others Guru releases 4th-quarter portfolio Ronald Muhlenkamp,Chuck Royce,NWQ Managers,Jim Sim - Ronald Muhlenkamp Gains 4 New Holdings, Sells 2 Others
Ronald Muhlenkamp (Trades, Portfolio), the founder and portfolio manager of Muhlenkamp & Co. Inc., established four new holdings and exited two others in the final quarter of 2016. More...

MUHLENKAMP, BUYS, SELLS, 4Q


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Oaktree Buys Bellatrix Exploration Firm acquires new energy holding Howard Marks,Ronald Muhlenkamp,Jim Simons - Oaktree Buys Bellatrix Exploration
Oaktree Capital Management acquired a new holding in Bellatrix Exploration Ltd. (NYSE:BXE) on Oct. 4. More...

MARKS, OAKTREE, OIL, BUY


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Ronald Muhlenkamp Sells Allegiant, Microsoft, Apple Largest sales by investor during second quarter Jeff Ubben,Ronald Muhlenkamp - Ronald Muhlenkamp Sells Allegiant, Microsoft, Apple
Ronald Muhlenkamp (Trades, Portfolio) is the founder and president of Muhlenkamp & Company Inc. and portfolio manager for the company's self-named mutual fund (MUHLX). The following are his largest sales of the second quarter. More...

SELL, TECHNOLOGY, MUHLENKAMP


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Ronald Muhlenkamp Sells JPMorgan, Morgan Stanley Guru also sells LinkedIn, Delta Airlines in 1st quarter Ronald Muhlenkamp,Barrow Hanley Mewhinney & Straus - Ronald Muhlenkamp Sells JPMorgan, Morgan Stanley
Ronald Muhlenkamp (Trades, Portfolio) is a patient value investor and the founder and president of Muhlenkamp & Company Inc., and portfolio manager for the company's self-named mutual fund. During the first quarter he sold shares in the following stocks: More...

  • Currently 5.00/5

Rating: 5.0/5 (2 votes)

Peter Lynch Targets Undervalued Airline Companies Gurus invest in hot airline industry David Dreman,Ronald Muhlenkamp,David Tepper - Peter Lynch Targets Undervalued Airline Companies
In early June, the Peter Lynch screen featured two airline companies, Allegiant Travel Co. (NASDAQ:ALGT) and Southwest Airlines Co. (NYSE:LUV), as two of the most undervalued companies based on their earnings lines. Due to potential upside in the airline industry, many gurus are increasing their positions in airline stocks. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Ronald Muhlenkamp Sells Stakes in Medtronic and State Street Guru invests in ETF in 4th quarter Ronald Muhlenkamp - Ronald Muhlenkamp Sells Stakes In Medtronic And State Street
Ronald Muhlenkamp (Trades, Portfolio), founder and president of Muhlenkamp & Co. Inc. and portfolio manager for its mutual fund, acquired half a dozen new holdings in the fourth quarter, but his biggest transactions were divestitures. More...

  • Currently 3.00/5

Rating: 3.0/5 (1 vote)

Muhlenkamp Bullish on Healthcare, Sees Limited Opportunities Elsewhere Ronald Muhlenkamp gives his market, investment insights at seminar Ronald Muhlenkamp - Muhlenkamp Bullish On Healthcare, Sees Limited Opportunities Elsewhere
Muhlenkamp and Company hosted an investment seminar on Dec. 3, providing keen insights on where founder Ronald Muhlenkamp sees the economy, and by extension the stock markets, going next. Muhlenkamp, the portfolio manager for its namesake Muhlenkamp Fund, spoke for the first half of the seminar. His son and co-manager Jeff Muhlenkamp took over for the last half. More...

ECONOMY,MUHLENKAMP,STRATEGY


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Ronald Muhlenkamp's Highest-Yielding Stocks JPMorgan and Teva Pharmaceutical top the list Ronald Muhlenkamp - Ronald Muhlenkamp's Highest-Yielding Stocks
Ronald Muhlenkamp is the founder and president of Muhlenkamp & Company Inc. and the portfolio manager for the company's mutual fund. His portfolio is composed of 64 stocks with a total value of $340 million. The following are the stocks in his portfolio with the highest growing yield. More...

  • Currently 5.00/5

Rating: 5.0/5 (1 vote)

Monitoring Economies around the Globe - Muhlenkamp Memorandum Q3 Jeff talks about Japan’s quantitative easing, Greece’s debt problem, China’s growth challenges, more Ronald Muhlenkamp - Monitoring Economies Around The Globe - Muhlenkamp Memorandum Q3
During our August 27, 2015 conference call, Tony Muhlenkamp, President, and Jeff Muhlenkamp, Investment Analyst and Co-Manager, discussed what’s been going on this past quarter in the U.S. and abroad. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Ronald Muhlenkamp Weighs In on Current Valuations in the Market It is easy to find good companies; it is hard to find good companies that are cheap Ronald Muhlenkamp - Ronald Muhlenkamp Weighs In On Current Valuations In The Market
Ronald Muhlenkamp isn't too worried about about the short-term market volatility. More...

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK